Christoph Plöger

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 613 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, Anna Maria Fink, Raymonde Busch et al. · Blood · 2014 · 117 citations

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Manuel Barreto Miranda, Michael Lauseker, M-P Kraus et al. · Leukemia · 2016 · 87 citations · Full text

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Barbara Eichhorst, Anna‐Maria Fink, Raymonde Busch et al. · Blood · 2013 · 55 citations

Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht et al. · HemaSphere · 2020 · 44 citations · Full text

Quality Of Life, Mixed-phenotype Acute Leukemia, Pharmacotherapy +19